GSK, Regeneron and UK Biobank In Gene Sequencing Initiative
GlaxoSmithKline and the Regeneron Genetics Center have joined forces with the UK Biobank to sequence genes from its 500,000 participants in an effort to improve drug discovery and disease diagnosis. The first data are due within a year.
You may also be interested in...
Regeneron is pointing to early research in genetics as the lifeline that will deliver new drugs into the clinic as Eylea matures, new blockbusters have yet to materialize and investors grow restless.
BioLineRx buys Agalimmune and its alpha Gal candidate for melanoma and possibly other oncology indications. Japan's Ono signs an R&D agreement with Switzerland's Numab, while Boston biotechs Vedantra and Neon will collaborate on potential cancer vaccines.
Amgen will pay $415 million to enhance the Thousand Oaks, California-based biotechnology powerhouse's drug discovery and development capabilities through the acquisition of deCODE Genetics, nearly three years after the Icelandic genome sequencer emerged from bankruptcy (scripintelligence.com, 22 January 2010).